Results 231 to 240 of about 114,702 (262)

A Novel Covalent Bruton’s Tyrosine Kinase Inhibitor

Synfacts, 2021
openaire   +1 more source

Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia

Hematology/Oncology Clinics of North America, 2021
Masa Lasica, Constantine S. Tam
openaire   +1 more source

Treatment of renal cell carcinoma: Current status and future directions

Ca-A Cancer Journal for Clinicians, 2017
Pedro Coelho Barata, Brian I Rini
exaly  

Synthesis of a Bruton’s Tyrosine Kinase Inhibitor

Synfacts, 2021
openaire   +1 more source

Lung cancer: New biological insights and recent therapeutic advances

Ca-A Cancer Journal for Clinicians, 2011
Suresh S Ramalingam, Fadlo R Khuri
exaly  

Bruton tyrosine kinase inhibitors for chronic lymphocytic leukemia

Cochrane Database of Systematic Reviews, 2021
Jacob Schmelz, Philip Heesen, Anish Patnaik, Travis Holder, Hun J Lee, Donald A Molony   +5 more
openaire   +1 more source

Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management

Nature Reviews Clinical Oncology, 2022
Lecia V Sequist, Jessica J Lin
exaly  

Applications of Bruton Tyrosine Kinase Inhibitors in Dermatology

Journal of Drugs in Dermatology
Cleo, Whiting, Sara Abdel, Azim, Adam, Friedman   +2 more
openaire   +2 more sources

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Cell, 2020
Markus Hoffmann, Nadine Krüger, Tobias S Schiergens   +2 more
exaly  

Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase

ChemMedChem, 2006
Zhengying, Pan, Heleen, Scheerens, Shyr-Jiann, Li, Brian E, Schultz, Paul A, Sprengeler, L Chuck, Burrill, Rohan V, Mendonca, Michael D, Sweeney, Keana C K, Scott, Paul G, Grothaus, Douglas A, Jeffery, Jill M, Spoerke, Lee A, Honigberg, Peter R, Young, Stacie A, Dalrymple, James T, Palmer   +15 more
openaire   +2 more sources